Form 4: TScan Therapeutics Director Barbara Klencke Buys Shares and Reports Trust Holdings

Director Barbara Klencke reports purchasing TScan Therapeutics shares and discloses holdings through a family trust.

Summary

• On September 23, 2024, Barbara Klencke, a director of TScan Therapeutics, acquired 5,000 shares of the company's voting common stock at a price of $5.29 per share.
• Following this transaction, Klencke directly owns 45,000 shares.
• Klencke also indirectly owns 25,000 shares through the Klencke Huestis Trust, where she serves as co-trustee.
• Klencke disclaims beneficial ownership of the trust's shares except to the extent of her pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a routine disclosure of a director's share purchase. While insider buying can be seen as positive, it's a single transaction and doesn't provide a comprehensive view of the company's prospects.

Positives

• The director's purchase of shares could be interpreted as a positive signal about her confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide investors with insights into the actions of company insiders, such as directors and officers.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment.

Key Dates